drugset / Trial / NCT00600821

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

NCT00600821

Phase 2 Completed 118 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.

Timeline

Start
2008-04
Primary completion
2011-04
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg Oral
Comparator Bevacizumab Monoclonal antibody 15 mg/kg Intravenous
Background Carboplatin Small molecule 6 unknown Intravenous
Background Paclitaxel Small molecule 200 mg/m2